Pfizer acquires Metsera for $10 billion in the obesity drug market
November 9, 2025
Pfizer announced the acquisition of biotech company Metsera for $10 billion, competing against Novo Nordisk. Metsera is developing experimental drugs for obesity, and this deal highlights the significant demand in this market. Novo decided to withdraw from the bidding process due to concerns over antitrust risks. Pfizer views this agreement as crucial for potential revenues that could reach $11 billion annually by 2040. Analysts accept that Pfizer is investing in developmental possibilities, even though Metsera's products are still in early stages of development.